High-flow oxygen therapy for the management of patients with acute exacerbation of cystic fibrosis

Arnaud W. Thille, Florent Joly, Nicolas Marjanovic, Jean-Pierre Frat

CHU de Poitiers, Réanimation Médicale, Poitiers, France; INSERM CIC 1402 - ALIVE, Université de Poitiers, faculté de Médecine et Pharmacie, Poitiers, France; CHU de Poitiers, Service d’Accueil des Urgences, Poitiers, France

Correspondence to: Arnaud W. Thille. Réanimation Médicale, CHU de Poitiers, 2 rue la Milétrie, 86021 Poitiers Cedex, France. Email: aw.thille@gmail.com.

Provenance: This is an invited Editorial commissioned by Section Editor Guo-Wei Tu, MD, PhD (Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China).


Submitted Nov 20, 2018. Accepted for publication Nov 27, 2018. doi: 10.21037/atm.2018.11.67

View this article at: http://dx.doi.org/10.21037/atm.2018.11.67

Cystic fibrosis is an autosomal recessive genetic disease that provokes dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR). The disease occurs most often from birth and affects mainly the lungs. This protein dysfunction directly provokes thick mucus into bronchi promoting pulmonary infections and leading to development of chronic obstructive pulmonary disease (COPD), followed by chronic respiratory failure. Cystic fibrosis also affects intestinal function, leading to pancreatic insufficiency and malnutrition that may alter muscular function and worsen respiratory failure. Its evolution is marked by iterative episodes of acute-on-chronic respiratory failure with hypercapnia.

Noninvasive ventilation: the usual treatment for acute exacerbation of cystic fibrosis

Although there exists no specific guidelines to be applied in this setting, the patients with cystic fibrosis experiencing acute exacerbation are commonly treated by noninvasive positive pressure ventilation (NIV). Among 36 adult and pediatric experienced centers, a French survey has shown that all of them used NIV as first-line treatment in management of patients with acute respiratory failure (1). NIV is also commonly continued at home in stable patients with persistent hypercapnia, even without respiratory acidosis (1). Indeed, though pooling of all randomized controlled trial it has been found that NIV may be useful in stable patients for airway clearance complementarily to chest physiotherapy and that it may improve gas exchange during sleep as compared to standard oxygen in the most severe patients (2). However, the impact of NIV on pulmonary exacerbations and disease progression remain unclear.

Unlike cases involving patients with cystic fibrosis, the continuation of NIV at home in patients with usual form of COPD (tobacco related) and without sleep apneas remains debated (3-5). By contrast, the beneficial effects of NIV as a means of reversing acute respiratory failure in COPD patients are well-demonstrated (6-8). NIV reduces respiratory rate, hypercapnia and the sensation of dyspnea by decreasing work of breathing and by improving alveolar ventilation. NIV reduces the need for intubation and, all in all, it improves survival of COPD patients admitted to intensive care unit (ICU) for acute hypercapnic respiratory failure. Recent European/American clinical practice guidelines have strongly recommended NIV for COPD patients with acute respiratory failure, but only in case of respiratory acidosis (pH < 7.35) (9). Whereas NIV is not recommended as a means of preventing the development of respiratory acidosis in common forms of COPD with stable hypercapnia, it is routinely used at home in patients with cystic fibrosis as a means of preventing acute exacerbation (1,2).
**High-flow nasal cannula oxygen therapy (HFOT) versus noninvasive ventilation (NIV) in adult patients with cystic fibrosis: results from a randomized crossover physiological study**

HFOT is an oxygen technique offering greater comfort and more efficient oxygenation than standard oxygen (10). HFOT is increasingly used, particularly in patients with acute hypoxemic respiratory failure (11). A large randomized controlled trial has found that mortality of patients with acute hypoxemic respiratory failure was lower when they were treated with HFOT than with standard oxygen or NIV (10). However, to date, no randomized controlled trial has been conducted in COPD patients or in patients with cystic fibrosis.

In a recent issue of *Annals of Intensive Care*, Sklar and colleagues have compared NIV versus HFOT in adult patients admitted to respiratory ward for acute exacerbation of cystic fibrosis (12). In this physiological prospective crossover study performed in a single center in Canada, 15 patients who had been stabilized over median 3 days under NIV were included. They received in random order 30 minutes of HFOT and 30 minutes of NIV with a washout period of 10 minutes under standard oxygen between the two strategies of oxygenation and at the end of the study. Patient effort was estimated using diaphragm ultrasound by measuring diaphragm thickening fraction (TFdi) as a surrogate measure for work of breathing (13). All patients had obstructive spirometric pattern; the ratio of forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) was 45% in median (IQR, 42–52%), and FEV1 was 800 mL (IQR, 600–1,000 mL), i.e., 24% (IQR, 20–26%) of predicted volume. Body mass index was 19 kg/m² (IQR, 17–22 kg/m²) and 73% of patients had pancreatic insufficiency. At admission, pH was 7.39 mmHg (IQR, 7.38–7.41 mmHg) and PaCO₂ was 53 mmHg (IQR, 49–63 mmHg).

As compared to baseline, HFOT set with a flow of 45 L/min (IQR, 45–55 L/min) and a FiO₂ of 30% (IQR, 25–35%), significantly reduced respiratory rate from 21 (IQR, 17–26) breaths per minute to 18 (IQR, 13–20) and minute ventilation from 6.9 L/min (IQR, 5.3–11.5 L/min) to 5.0 L/min (IQR, 4.2–6.6 L/min). HFOT even increased tidal volumes as compared to NIV delivered with an inspiratory positive airway pressure (IPAP) of 14 cmH₂O (IQR, 12–18 cmH₂O) and an expiratory positive airway pressure (EPAP) of 6 cmH₂O (IQR, 6–6 cmH₂O). Despite low dyspnea score at baseline, comfort was better with both HFOT and NIV compared with standard oxygen. No changes were observed for pulse oximetry, transcutaneous CO₂ measurements or patient effort, which was estimated by diaphragm thickening fraction measured with ultrasound. The authors concluded that HFOT was associated with decreased work of breathing per minute as compared to standard oxygen since patient effort per breath, as assessed by TFdi, remained similar regardless the oxygenation device used, while a lower respiratory rate was observed with HFOT. These findings suggest that HFOT may be the most comfortable oxygenation strategy and may decrease the respiratory rate and work of breathing as compared to standard oxygen similarly to NIV. Although measurement of work of breathing using ultrasound is not the reference method and remains debatable (13), comfort improvement and reduction in respiratory rate are two beneficial effects of major interest for patients frequently needing prolonged sessions of NIV at home or at hospital in case of acute exacerbation. In this study, 60% of patients had NIV at home prior to admission and 80% had oxygen. Consequently, HFOT may be considered as a particularly useful for these patients.

**High-flow oxygen therapy in COPD and hypercapnic patients: what is the future?**

As compared to standard oxygen, HFOT improves oxygenation and decreases respiratory rate and work of breathing in patients with acute hypoxemic respiratory failure (14,15). Interestingly, the higher the baseline PaCO₂, the greater the reduction in work of breathing (14). Moreover, minute ventilation decreases without change in PaCO₂ meaning that continuous washout of dead space in the upper airway may be the main factor contributing to decrease work of breathing. The other factor that may contribute to decrease work of breathing is the positive end-expiratory pressure (PEEP) effect generated by continuous delivery of high airflow. This effect may decrease work of breathing as NIV did, especially in COPD patients with dynamic hyperinflation and intrinsic PEEP. However, the PEEP level generated with HFOT does not exceed 2–3 cmH₂O even with a flow rate of 50 L/min (16), and continuous washout of dead space in the upper airway seems to be the main factor contributing to decreased patient respiratory effort.

In a population of stable COPD patients, a physiologic study has found that the higher the airflow rate, the greater the reduction in PaCO₂ while added leakage further
decreased PaCO$_2$ and increased pressure in the upper airway had no effect (17). Finally, a recent physiological study including stable COPD patients showed that HFOT significantly decreased work of breathing as compared to standard oxygen, although this reduction was less than with NIV (18). Patient respiratory effort as assessed by measurement of diaphragmatic pressure time product with an esophageal and gastric catheter, was 283±82 cmH$_2$O·s/min with standard oxygen and decreased to 157±57 with HFOT set at 30 L/min open mouth, 143±49 with HFOT closed mouth, and further decreased to 102±43 with NIV (18).

Although beneficial effects of HFOT have been reported in several physiological studies, no randomized controlled trial to date has compared HFOT versus standard oxygen or NIV in COPD patients with acute exacerbation. Only observational studies in patients of mild severity (19,20) or case reports in patients with acute respiratory failure who did not tolerate NIV have reported efficacy of HFOT as a means of reversing respiratory acidosis (21,22). In a recent randomized controlled trial comparing HFOT with NIV in more than two hundred patients admitted at emergency room for acute respiratory failure of various origin, nearly half of included patients had underlying COPD or hypercapnia at inclusion (23). In this study, the use of HFOT was non-inferior to NIV with an intubation rate of 7% with HFOT versus 13% with NIV, suggesting that HFOT may be as effective as NIV. HFOT may be an alternative not only to NIV in case of intolerance or inability to carry out NIV, but also and especially an alternative to standard oxygen with the aim of improving comfort while decreasing NIV duration and the risk for intubation. In a recent pilot study, HFOT use improved comfort during breaks off NIV without modifying total NIV duration (24). However, a large French multicenter randomized controlled trial will soon begin with the aim of comparing the effect of HFOT or standard oxygen between NIV sessions on the number of ventilator-free days at day 28 in COPD patients admitted to ICU for acute hypercapnic respiratory failure (25). The hypothesis of this study is that HFOT may decrease the duration of mechanical ventilation, i.e., the duration of NIV and/or the risk for intubation.

The study by Sklar and colleagues shows beneficial effects of HFOT in patients with cystic fibrosis as compared to standard oxygen and NIV. These patients are frequently treated with long term oxygen therapy and prolonged sessions of NIV, and the beneficial effects observed in this study on comfort and respiratory rate with HFOT could be provide a new oxygenation strategy for management of these patients.

**Acknowledgements**

None.

**Footnote**

Conflicts of Interest: AW Thille reports to have received travel expenses coverage to attend scientific meetings from Fisher & Paykel, Covidien, Maquet, and General Electrics, and no personal income from any company; JP Frat reports to have received consulting fees from Fisher & Paykel; the other authors have no conflicts of interest to declare.

**References**


Cite this article as: Thille AW, Joly F, Marjanovic N, Frat JP. High-flow oxygen therapy for the management of patients with acute exacerbation of cystic fibrosis. Ann Transl Med 2018;6(Suppl 2):S113. doi: 10.21037/atm.2018.11.67